PRODUCT DETAILS VIEW ALL PRODUCTS

Nordys Tablets (Rifaximin)

  • Each tablet contains Rifaximin 200/400/550 mg tablets.
  • Rifaximin Tablet 200mg: For infections diarrhoea in adults.Rifaximin 400mg: For the treatment of hepatic encephalopathy. Rifaximin Tablet 550 mg: For Irritable Bowel Syndrome. For Reduction in Risk of Overt Hepatic Encephalopathy (HE) Recurrence in Patients ≥ 18 years of Age.
  • Rifaximin is a semi-synthetic derivative of rifampin and acts by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase blocking one of the steps in transcription. This results in inhibition of bacterial protein synthesis and consequently inhibits the growth of bacteria.
  • Dosage for diarrhoea in adults: One 200 mg tablet taken 3 times a day.Dosage for Hepatic Encephalopathy: The recommended dose of Rifaximin is one 400mg tablet taken orally every 8 hours. Dosage for Irritable Bowel Syndrome with Diarrhea (IBS-D): The recommended dose of Rifaximin is one 550 mg tablet taken orally three times a day for 14 days. Patients who experience a recurrence of symptoms can be retreated up to two times with the same dosage regimen.
  • History of hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components of Nordys tablets.
  • Nordysis not effective in diarrhea complicated by fever and/or blood in the stool or diarrhea due to pathogens other than E. coli. If diarrhea symptoms get worse or persist for more than 24 to 48 hours, discontinue Nordys and consider alternative antibiotics. Caution should be exercised when Rifaximin is administered to patients with severe hepatic impairment. Clostridium difficile-Associated Diarrhea: Evaluate if diarrhea occurs after therapy or does not improve or worsens during therapy.
  • There is no data available regarding the safety and effectiveness of rifaximin during pregnancy and lactation. The safety and effectiveness of rifaximin has not been established in pediatric patients less than 12 years of age with infectious diarrhea or in patients less than 18 years of age for hepatic encephalopathy and IBS-diarrhoea.
  • P-glycoprotein Inhibitors -Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs such as azithromycin, ketoconazole, erythromycin, cyclosporine etc. significantly increases the systemic exposure of rifaximin. Changes in INR values have been observed when rifaximin is co-administered with warfarin. Monitor INR and prothrombin time. Dose adjustment of warfarin may be needed to maintain target INR range.
  • Headache, peripheral edema, nausea, dizziness, fatigue, ascites and elevated AST.
  • Anti-Diarrhoels